Why the study?
Hand, foot and mouth disease is an emerging infection with pandemic potential, and knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research.
Does natural infection with specific enteroviruses elicit cross-neutralizing antibodies against other HFMD-causing enteroviruses in children?
Does natural infection with specific enteroviruses elicit cross-neutralizing antibodies against other HFMD-causing enteroviruses in children?
Natural infection with HFMD-causing enteroviruses elicits strong homotypic neutralizing antibody responses but poor heterotypic cross-neutralization, highlighting the need for multivalent vaccines.
Seropositivity rise post-homotypic HFMD may inform immunity surveillance; leaves open cross-neutralization extent for vaccines.
Hand, foot and mouth disease (HFMD) is an emerging infection with pandemic potential. Knowledge of neutralizing antibody responses among its pathogens is essential to inform vaccine development and epidemiologic research. We used 120 paired-plasma samples collected at enrollment and >7 days after the onset of illness from HFMD patients infected with enterovirus A71 (EV-A71), coxsackievirus A (CVA) 6, CVA10, and CVA16 to study cross neutralization. For homotypic viruses, seropositivity increased from <60% at enrollment to 97%-100% at follow-up, corresponding to seroconversion rates of 57%-93%. Seroconversion for heterotypic viruses was recorded in only 3%-23% of patients. All plasma samples from patients infected with EV-A71 subgenogroup B5 could neutralize the emerging EV-A71 subgenogroup C4. Collectively, our results support previous reports about the potential benefit of EV-A71 vaccine but highlight the necessity of multivalent vaccines to control HFMD.
No takes yet. Share an insight, caveat, or question.
Nguyet et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: